Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) and Liminatus Pharma (NASDAQ:LIMN – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Insider & Institutional Ownership 3.8% of Inhibikase […]